In this clinic-focused program, review current and emerging strategies for personalizing AML treatment with expert-authored commentaries, and an on-demand Webcast capturing expert discussion from the 2018 hematologic malignancies symposium in San Diego. Then download the meeting slidesets and decision support resources on prognostic factors and key AML clinical trials to help guide your AML treatment recommendations.
New targeted agents are improving outcomes in newly diagnosed and relapsed/refractory AML. How can we optimize our diagnostic and treatment approaches for patients based on karyotype, FLT3 status, and other biomarkers?
New drugs and drug combinations, particularly targeted therapies, are changing the treatment paradigm for patients with newly diagnosed and relapsed/refractory AML.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.